Qual é o preço para Exopharm Limited (EX1)

O preço para Exopharm Limited (EX1) é $0.00700343

Qual é a capitalização de mercado para Exopharm Limited (EX1)

A capitalização de mercado para Exopharm Limited (EX1) é $637.31K

Receita de Exopharm Limited (EX1)

Exopharm Limited is an Australian clinical-stage firm dedicated to developing groundbreaking therapeutics utilizing extracellular vesicles (EVs). Its core technologies include an extracellular vesicle positioning system (EVPS), which facilitates the precise targeting of exosomes by attaching specific molecules to their surface, guiding them to particular tissues or cell types. Another innovation is oligonucleotide packing, designed to optimize therapeutic delivery by preferentially loading specific RNA molecules into exosomes as medicinal cargo. Additionally, Exopharm employs ligand-based exosome affinity purification for effectively isolating and refining exosomes from biological fluids such as blood and cell culture media. The company's engineered EV product portfolio features Fortrexo CoV, aimed at treating SARS-CoV-2 infections; Cognevo, developed for neurodegenerative diseases; and PlexoDox, intended for cancer treatment. Exopharm Limited also maintains a research collaboration with Showa Denko Materials Co., Ltd. The company was founded in 2013 and is headquartered in Melbourne, Australia.

Ano	Receita	Alterar
Não há dados suficientes para as datas fornecidas.

Ano

Receita

Alterar

Não há dados suficientes para as datas fornecidas.

Empresa	Receita	Diferença de Receita	País
Vertex Pharmaceuticals Incorporated VRTX.US	$12.62B	-	US
Argenx SE ARGX.US	$6.02B	-	NL
Lonza Group AG LONN.SW	-	-	CH
Samsung Biologics Co.,Ltd. 207940.KS	-	-	KR
UCB S.A. UCB.BR	$10.11B	-	BE

Empresa

Receita

Diferença de Receita

País